Hepatic encephalopathy nursing reference: assessment, interventions, and clinical management

Hepatic encephalopathy (HE) is a brain dysfunction caused by liver failure or portosystemic shunting. The liver loses its ability to convert toxic byproducts — primarily ammonia — into harmless compounds, and those toxins reach the brain. The result ranges from subtle cognitive slowing detectable only by specialized testing all the way to coma. Recognizing which grade a patient is in, identifying and treating the precipitant, and titrating lactulose correctly are the three core nursing skills for HE management.

Pathophysiology: how ammonia damages the brain

The ammonia hypothesis is the central model for HE pathophysiology, though it operates alongside systemic inflammation and gut dysbiosis in a way that makes the full picture more than just “too much ammonia.”

Gut-liver axis. Colonic bacteria (primarily urease-producing organisms like Helicobacter, Proteus, and Klebsiella) degrade dietary protein and urea into ammonia (NH₃). In a healthy liver, portal blood delivers this ammonia to hepatocytes, which convert it to urea via the urea cycle (the Krebs-Henseleit cycle) for renal excretion. When hepatocyte mass is critically reduced — through cirrhosis, acute liver failure, or portosystemic shunting — ammonia bypasses this detoxification step and enters systemic circulation.

Astrocyte dysfunction. Ammonia crosses the blood-brain barrier and is taken up by astrocytes, the primary brain cells capable of ammonia metabolism. Astrocytes convert ammonia to glutamine via glutamine synthetase. In acute liver failure this glutamine accumulation causes osmotic astrocyte swelling and cerebral edema — the mechanism behind herniation risk. In chronic cirrhosis, prolonged exposure produces Alzheimer type II astrocytosis: enlarged pale astrocytes with swollen nuclei, which impair normal neurotransmission.

Neuroinflammation. Systemic inflammation — from gut bacterial translocation, infections, or cytokine release — potentiates the neurotoxic effect of ammonia even when ammonia levels are only modestly elevated. This explains why patients with cirrhosis who develop spontaneous bacterial peritonitis (SBP) or a urinary tract infection (UTI) can develop HE with relatively low ammonia levels.

Altered neurotransmitters. Hyperammonemia elevates inhibitory neurotransmitter tone (enhanced GABAergic signaling, increased brain benzodiazepine receptor ligands), contributing to the sedation and cognitive slowing seen in overt HE. Manganese, which accumulates in cirrhosis due to reduced biliary excretion, deposits in the globus pallidus and is visible as T1-weighted hyperintensity on MRI — one specific imaging correlate of chronic HE.

Types of hepatic encephalopathy

The current classification (ISHEN/AASLD) organizes HE by underlying cause and clinical course:

Type A — Acute liver failure. HE occurring in a patient with no prior liver disease, where liver failure develops within 26 weeks. Carries the highest risk of cerebral edema and herniation because the brain has not had time to adapt. This is a medical emergency requiring ICU-level care.

Type B — Bypass without intrinsic liver disease. HE from portosystemic shunting in a patient whose liver parenchyma is intact. Rare in general nursing practice but important to recognize: portal hypertension does not always mean cirrhosis.

Type C — Cirrhosis-related. The form students encounter most often. Further divided by clinical course:

• Episodic: discrete, identifiable HE episodes (most common; usually triggered by a precipitant)
• Persistent: cognitive and behavioral changes that do not fully resolve between episodes
• Minimal/covert: no clinically apparent changes, detected only by psychometric or neurophysiological testing

Covert vs. overt distinction. Covert HE includes minimal HE (Grade 0 by West Haven) and Grade 1. Overt HE starts at Grade 2. This distinction matters because minimal HE — the most prevalent form — is invisible without testing. Patients with minimal HE have impaired driving performance, reduced work productivity, and quality of life deficits that go undetected on routine clinical assessment.

Precipitating factors: find the trigger first

HE in a patient with known cirrhosis is almost always triggered by a reversible precipitant. Identifying and treating that precipitant is the most important clinical action — ammonia-lowering therapy alone will not sustain improvement if the underlying trigger persists.

West Haven Criteria: clinical stages with nursing-observable signs

The West Haven Criteria is the standard grading system for overt HE. Nurses are typically the first to detect changes across these grades because they are at the bedside continuously.

Asterixis assessment: technique and clinical significance

Asterixis — often called the “liver flap” — is the cardinal motor sign of overt HE, though it is not specific to liver disease alone.

Assessment technique:

1. Ask the patient to extend both arms forward with wrists dorsiflexed (hands pointing toward the ceiling).
2. Have the patient hold this position for 15–30 seconds with eyes open or closed.
3. A positive result is a brief, irregular, arrhythmic lapse in sustained posture — the hands flap downward then rapidly return to position. This is not a tremor; it is the absence of sustained muscle tone at irregular intervals.
4. Assess both hands simultaneously — unilateral asterixis suggests structural brain lesion, not metabolic encephalopathy.

Grading asterixis:

• Absent: no lapses over 30 seconds
• Mild: 1–2 isolated lapses; patient may not notice
• Moderate: multiple lapses; prominent flapping; corresponds to Grade 2 HE
• Severe: too frequent to count; movement nearly continuous; Grade 3 HE

Conditions that mimic asterixis: Uremia (renal failure), hypercarbia (CO₂ retention in COPD/respiratory failure), hypomagnesemia, hypoglycemia, drug toxicity (anticonvulsants, lithium), and Wilson’s disease can all produce asterixis. In a patient with known cirrhosis, asterixis is HE until proven otherwise — but the cause of encephalopathy should always be confirmed and alternative etiologies considered if the clinical picture does not fit.

Clinical significance: Asterixis typically appears in Grades 2–3 and is not present in Grade 0–1 (it requires adequate muscle tone to demonstrate) or Grade 4 (the patient cannot cooperate with testing). Its appearance is a reliable indicator that encephalopathy has progressed to overt HE and that the treatment threshold has been crossed.

Diagnostics in hepatic encephalopathy

Serum ammonia. A normal ammonia level has high negative predictive value — a normal result makes HE much less likely. However, a single elevated ammonia level is neither specific nor sufficient for diagnosis: 10–15% of patients with overt HE have normal ammonia, and some patients with very high ammonia show no clinical symptoms. Serial ammonia measurements are less useful than clinical assessment of treatment response. Important pre-analytical caveats: samples must be transported on ice, processed within 15–30 minutes, and drawn without a tourniquet (fist-clenching falsely elevates ammonia). Venous samples are acceptable and equivalent to arterial.

Number connection test (NCT). The patient connects numbered circles from 1 to 25 as quickly as possible. Time in seconds is measured. A benchmark: completion time should be no longer than the patient’s age in years (a 60-year-old should complete in ≤60 seconds). The NCT detects minimal and Grade 1 HE that the standard neurological exam misses.

Psychometric hepatic encephalopathy score (PHES). A battery of five pencil-and-paper tests that maps cognitive function affected by HE: number connection test A and B, digit symbol test, serial dotting, and line tracing. A composite score <–4 standard deviations from age-adjusted norms is diagnostic for minimal HE. PHES is the reference standard for covert HE detection.

EEG. Produces high-amplitude, low-frequency waves in overt HE — sensitive but not specific. Most useful for ruling out non-convulsive seizure activity as the cause of altered consciousness, particularly in Grade 3–4 patients who cannot follow commands.

MRI. In acute liver failure, diffuse cerebral edema on DWI or FLAIR sequences indicates herniation risk. In chronic cirrhosis, T1-weighted hyperintensity in the globus pallidus reflects manganese deposition — a marker of chronicity but not a diagnostic tool for individual episodes. CT/MRI is primarily used to exclude other diagnoses (subdural hematoma, stroke) before attributing altered consciousness to HE.

Priority nursing interventions

Identify and treat the precipitant

This is the most important step and must occur simultaneously with ammonia-lowering treatment. A patient with HE from an untreated GI bleed who receives lactulose will not improve until the bleeding is controlled and the blood is cleared from the gut. Systematically assess for each precipitant: check stool for occult blood, review temperature and WBC trends, review diuretic and sedative medication lists, check BUN and creatinine, and confirm bowel function is adequate.

Ammonia reduction

Lactulose is first-line. See the detailed section below. The endpoint is 2–3 soft stools per day — lactulose must be titrated to this, not given as a fixed dose. Document stool frequency and consistency on every shift.

Rifaximin is second-line and adjunct. See the detailed section below.

Dietary protein. Per AASLD/EASL guidelines, target 1.2–1.5 g/kg/day of protein. Do not restrict protein. Protein-malnourished cirrhotic patients have worse survival, more muscle wasting (sarcopenia), and actually more HE episodes than well-nourished patients. Vegetable and dairy proteins are preferred over animal meat proteins when patients are intolerant of normal protein loads. Small frequent meals (4–6 per day) plus a late-evening snack prevent the fasting catabolic state that worsens ammonia production.

Neurological assessment

• Grade GCS or perform A&O×4 at minimum on every shift; more frequently in Grades 2–3
• Assess asterixis with each neurological check
• Document any change from baseline — families are invaluable reporters of subtle personality shifts (Grade 0–1 changes)
• Fall precautions from Grade 1 onward — confusion and motor dysfunction develop before patients appear visibly impaired
• Grade 3–4: position the head of bed at 30 degrees; assess gag reflex; have suction at bedside; monitor for aspiration

Bowel management

• Track all stools — date, time, consistency, estimated volume if output tube in place
• Lactulose can be given orally, via NG tube, or as a retention enema (300 mL in 700 mL water) if the patient cannot swallow
• Target 2–3 soft stools/day — too few stools means inadequate lactulose effect; too many creates dehydration and electrolyte imbalances
• Avoid constipating medications (opioids, antidiarrheals) without specific clinical indication

Fluid, electrolyte, and nutritional management

Hypokalemia alkalosis worsens HE by promoting renal ammonia production and shifting the NH₃/NH₄⁺ equilibrium toward the diffusible ammonia form. Monitor potassium closely and replace to maintain K⁺ ≥3.5 mEq/L. Avoid over-diuresis in patients on spironolactone and furosemide. For patients with cirrhosis and ascites, daily weights and abdominal girth measurements remain essential.

Medication review

Hold or minimize benzodiazepines, opioids, NSAIDs, and other CNS depressants. If benzodiazepine withdrawal is a concern (concurrent alcohol use disorder), discuss with the physician before discontinuing — withdrawal seizures can precipitate HE. Flumazenil (a benzodiazepine receptor antagonist) can briefly reverse HE symptoms in patients with exogenous benzodiazepine exposure, confirming the precipitant. Review the nursing lab values cheat sheet for ammonia, BUN, and electrolyte reference ranges.

Grade 3–4: advanced interventions

• Continuous neurological monitoring; immediate escalation to ICU if grade worsens
• Airway positioning; intubation if gag reflex is absent or airway cannot be protected
• If acute liver failure with Grade 3–4: ICP monitoring may be indicated; head-of-bed elevation; minimize stimulation; consider mannitol for intracranial hypertension
• TIPS procedure: can trigger or worsen HE in up to 30–50% of cirrhotic patients; post-procedure HE may require TIPS revision or occlusion for medically refractory cases
• Hepatic transplant evaluation: any patient with a first overt HE episode warrants transplant workup — one episode independently predicts mortality; median survival without transplant is under two years

Lactulose nursing: mechanism, titration, and education

Lactulose (1,4-β-galactosidofructose) is a non-absorbable synthetic disaccharide. It lowers blood ammonia through three mechanisms:

1. Acidification of gut lumen. Colonic bacteria ferment lactulose into short-chain organic acids (acetate, propionate, butyrate), lowering intraluminal pH. This converts ammonia (NH₃, which freely diffuses across membranes) into ammonium (NH₄⁺, which is ionized and cannot be absorbed). The ammonium is then excreted in stool.
2. Cathartic effect. The osmotic and acidic environment accelerates colonic transit, reducing the contact time for ammonia absorption.
3. Nitrogen trapping. The acidic environment promotes diffusion of NH₃ from blood into the gut lumen, where it is converted to NH₄⁺ and excreted.

Dosing. Lactulose is started at 20–30 g (30–45 mL) orally two to four times daily. This is the starting range, not the target dose. The endpoint is 2–3 soft stools per day. Titrate upward if stools are inadequate; titrate down if the patient develops diarrhea, bloating, or dehydration. Approximately 70–80% of patients improve with lactulose therapy.

Administration routes:

• Oral: standard; mix with juice to improve palatability if needed
• NG tube: effective; confirm placement and flush after
• Retention enema: 300 mL lactulose in 700 mL water; held 30–60 minutes; used for Grade 3–4 patients who cannot swallow and when rapid ammonia reduction is needed

Side effects to monitor:

• Diarrhea (most common; indicates dose is too high)
• Bloating, cramping, flatulence
• Dehydration and hyponatremia from excessive stool losses
• Aspiration risk if given orally to patients with altered swallowing

Patient and family education:

• “The goal is loose, soft stools — two or three times a day. That means the medicine is working.”
• Do not stop lactulose even if stools seem too soft — discuss dose adjustment with the nurse or provider first
• Avoid sugary drinks when mixing lactulose (fructose competes with fermentation)
• Family members: report confusion, unusual behavior, or change in sleep schedule immediately

Rifaximin: mechanism and nursing considerations

Rifaximin is a non-systemic, gut-selective antibiotic that reduces ammonia-producing bacteria in the colon. Unlike lactulose, it works upstream of ammonia production rather than trapping ammonia after formation.

Mechanism. Rifaximin binds to bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis. Because it is minimally absorbed (<0.4% bioavailability), it achieves very high concentrations in the gut lumen with negligible systemic exposure. This selective gut activity reduces urease-producing bacteria and directly reduces ammonia generation from dietary protein and urea.

Evidence base. The RFHE3001 trial (Bass et al., NEJM 2010) showed rifaximin 550 mg twice daily reduced the risk of overt HE recurrence by 58% compared to placebo over 6 months, and reduced hospitalizations for HE. It is now standard of care as adjunct therapy for secondary prevention alongside lactulose.

Dosing. 550 mg orally twice daily (for secondary prevention/adjunct). 400 mg three times daily is used in some acute protocols.

Nursing considerations:

• Rifaximin is expensive; verify prior authorization if transitioning from inpatient to outpatient
• Minimal drug interactions due to negligible systemic absorption — but check for any CYP3A4 interactions if the patient is on cyclosporine
• Can be continued during acute HE episodes alongside lactulose
• Does not replace lactulose — the two work through different mechanisms and are complementary

Zinc and BCAA: adjunct nutritional strategies

Zinc. Cirrhotic patients are almost universally zinc-deficient due to poor dietary intake, reduced intestinal absorption, and increased urinary zinc excretion from diuretic use. Zinc is a cofactor for enzymes in the urea cycle and glutamine synthetase, both of which are involved in ammonia detoxification. Serum zinc levels below 60 µg/dL are associated with increased risk of covert HE. Trials combining zinc supplementation with lactulose have shown improvement in NCT performance and reduced ammonia levels over 3–6 months. Zinc supplementation is not first-line but warrants consideration in malnourished cirrhotic patients with recurrent HE.

Branched-chain amino acids (BCAAs). In liver disease, BCAAs (leucine, isoleucine, valine) are preferentially catabolized by muscle for energy, leading to low plasma BCAA levels. BCAAs compete with aromatic amino acids (phenylalanine, tyrosine, tryptophan) for transport across the blood-brain barrier — when BCAAs are depleted, aromatic amino acids flood the brain, altering neurotransmitter synthesis and contributing to encephalopathy. Oral BCAA supplementation improves muscle mass and minimal HE symptoms. Intravenous BCAAs have not shown benefit for acute HE episodes. BCAAs can be used as a protein supplement for patients who are genuinely intolerant of standard dietary protein, allowing adequate nitrogen intake without worsening HE.

Complications of hepatic encephalopathy

Cerebral herniation. The most feared complication in acute liver failure (Type A HE). Rapid astrocyte swelling from glutamine accumulation causes diffuse cerebral edema. Uncal herniation manifests as Cushing triad: hypertension, bradycardia, and irregular respirations. Ipsilateral pupil dilation and decorticate/decerebrate posturing are late signs. This is a neurosurgical emergency. In cirrhosis-related HE, true herniation is rare — cerebral edema in chronic disease is less severe because the brain has adapted over time.

Aspiration pneumonia. Grade 3–4 HE significantly impairs protective airway reflexes. Aspiration is a leading cause of morbidity and mortality in patients with severe encephalopathy. Early intubation for airway protection, head-of-bed elevation, and avoiding oral intake in Grade 3–4 are the primary prevention strategies.

Acute kidney injury. Both HE and AKI are triggered by the same precipitants (sepsis, GI bleeding, hypovolemia), making them frequently co-occurring. AKI reduces renal ammonia excretion and worsens the encephalopathy. The AKI nursing reference covers hepatorenal syndrome, the most severe form of AKI in cirrhosis.

Spontaneous bacterial peritonitis (SBP). SBP is one of the most common HE precipitants in cirrhotic patients with ascites. It causes systemic inflammation that lowers the threshold for neurological dysfunction. Diagnostic paracentesis (cell count >250 PMNs/mm³ is diagnostic) and prompt cefotaxime therapy are required. Third-generation cephalosporins are first-line; albumin infusion (1.5 g/kg on day 1, 1 g/kg on day 3) reduces mortality by preventing hepatorenal syndrome. See the cirrhosis nursing reference for SBP details.

Persistent cognitive impairment. Recurrent overt HE episodes cause lasting neurocognitive damage. Patients with multiple episodes often have ongoing deficits in attention, processing speed, and working memory that persist even during apparent clinical recovery. This drives poor medication adherence, driving impairment, and employment loss — all reasons for early transplant evaluation.

NCLEX decision priorities

1. First assessment finding requiring immediate action. A patient with known cirrhosis becomes increasingly confused and exhibits asterixis. Priority: assess neurological status (GCS, orientation, asterixis severity), check ammonia level, review for precipitants (last bowel movement, signs of bleeding, fever), and prepare lactulose administration.

2. Lactulose titration endpoint. The correct clinical answer is 2–3 soft stools per day — not a specific mL dose, not “loose stool,” not “watery diarrhea.” If a patient on lactulose has 6 watery stools per day, the dose is too high. Reduce the dose.

3. Dietary protein guidance. The NCLEX may present protein restriction as a treatment option for HE. This is the historical approach and is now incorrect per current AASLD/EASL guidelines. Protein restriction worsens sarcopenia, decreases ammonia metabolism capacity, and increases mortality. The correct answer is 1.2–1.5 g/kg/day with preference for vegetable and dairy sources.

4. Asterixis assessment. Arms extended, wrists dorsiflexed, held for 15–30 seconds. A positive test is irregular, arrhythmic lapses — not fine tremor (which is a different finding). Grade 2–3 HE.

5. Precipitant identification is treatment. If a question asks about a patient with HE who has melena, the priority intervention is not to give lactulose — it is to address the GI bleed. Lactulose clears the existing ammonia load but more blood in the gut will continue producing ammonia until the bleed is stopped.

6. TIPS and HE. TIPS (transjugular intrahepatic portosystemic shunt) controls variceal bleeding but creates direct portosystemic shunting, meaning blood bypasses hepatic detoxification. Up to 30–50% of TIPS patients develop new or worsening HE. This is a known complication, not a treatment failure, but warrants close neurological monitoring post-procedure.

7. Grade 3–4 priorities. Airway. The brain is irreplaceable; without a patent airway all other interventions are futile. Suction at bedside, HOB elevated 30 degrees, assess gag reflex, escalate to ICU if Grade 3 worsens.

8. Medication avoidance. Benzodiazepines, opioids, and NSAIDs are contraindicated in HE. If a question shows a patient with HE and a prescription for lorazepam for anxiety, the nurse’s action is to clarify the order with the prescriber before administration.

For a full review of liver failure scoring tools and hepatorenal syndrome, see the liver failure nursing reference.